Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.

[1]  Min Ma,et al.  A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. , 2015, Biomaterials.

[2]  K. Seyfarth,et al.  PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy. , 2015, Molecular pharmaceutics.

[3]  H. Kuh,et al.  Improving drug delivery to solid tumors: priming the tumor microenvironment. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[4]  A. Elaissari,et al.  Administration strategies for proteins and peptides. , 2014, International journal of pharmaceutics.

[5]  J. Reusch,et al.  Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin , 2014, Diabetes, obesity & metabolism.

[6]  E. Hindié,et al.  Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors , 2014, The Journal of Nuclear Medicine.

[7]  Felix Kratz,et al.  A clinical update of using albumin as a drug vehicle - a commentary. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Yinan Zhong,et al.  Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. , 2014, Biomacromolecules.

[9]  Erkki Ruoslahti,et al.  A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[10]  T. Shin,et al.  Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy , 2014, Molecular Cancer Therapeutics.

[11]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[12]  I. Jambor,et al.  In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.

[13]  J. Reubi,et al.  Targeting GRPR in urological cancers—from basic research to clinical application , 2013, Nature Reviews Urology.

[14]  U. Dittmer,et al.  IFN‐α subtypes: distinct biological activities in anti‐viral therapy , 2013, British journal of pharmacology.

[15]  Jingqiu Cheng,et al.  Bombesin Analogue-Mediated Delivery Preferentially Enhances the Cytotoxicity of a Mitochondria-Disrupting Peptide in Tumor Cells , 2013, PloS one.

[16]  Dong Xu,et al.  Toward optimal fragment generations for ab initio protein structure assembly , 2013, Proteins.

[17]  E. Ruoslahti,et al.  De novo design of a tumor-penetrating peptide. , 2013, Cancer research.

[18]  Erkki Ruoslahti,et al.  Transtumoral targeting enabled by a novel neuropilin-binding peptide , 2012, Oncogene.

[19]  H. Vogel,et al.  Design of a novel tryptophan-rich membrane-active antimicrobial peptide from the membrane-proximal region of the HIV glycoprotein, gp41 , 2012, Beilstein journal of organic chemistry.

[20]  F. Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  F. Kratz,et al.  Clinical impact of serum proteins on drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[22]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[23]  M. Bradley,et al.  Peptides for cell-selective drug delivery. , 2012, Trends in pharmacological sciences.

[24]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[25]  W. Sebald,et al.  N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH. , 2011, International journal of pharmaceutics.

[26]  J. Andersen,et al.  Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.

[27]  Jingqiu Cheng,et al.  Selective apoptotic killing of solid and hematologic tumor cells by bombesin-targeted delivery of mitochondria-disrupting peptides. , 2010, Molecular pharmaceutics.

[28]  H. Vogel,et al.  Thermodynamics of the interactions of tryptophan-rich cathelicidin antimicrobial peptides with model and natural membranes. , 2008, Biochimica et biophysica acta.

[29]  R. Benya,et al.  International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States , 2008, Pharmacological Reviews.

[30]  Paolo Bernardi,et al.  BMAP-28, an Antibiotic Peptide of Innate Immunity, Induces Cell Death through Opening of the Mitochondrial Permeability Transition Pore , 2002, Molecular and Cellular Biology.

[31]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[32]  Min Huang,et al.  Molecularly targeted cancer therapy: some lessons from the past decade. , 2014, Trends in pharmacological sciences.

[33]  Jingqiu Cheng,et al.  Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery , 2011, Acta Pharmacologica Sinica.

[34]  A. Malik,et al.  Signaling mechanisms regulating endothelial permeability. , 2006, Physiological reviews.